Sironax has enrolled roughly half of the target population in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator tested alongside semaglutide in adults with obesity. The primary endpoints center on fat mass and body composition rather than weight alone, with lean mass preservation among the secondary measures. Preclinical models reported preferential fat loss and reduced muscle atrophy, though the compound remains investigational and unapproved.
Key Points
- Phase 2 trial of NAMPT activator SIR4156 reaches 50% enrollment
- Endpoints prioritize fat mass and body composition over total weight
- Combination with semaglutide targets lean mass preservation during weight loss
Longevity Analysis
Pharmacological weight reduction routinely strips skeletal muscle alongside fat, a trade-off with direct consequences for metabolic rate, glucose handling, fall risk and functional span in later decades. Targeting NAMPT places the intervention upstream in NAD+ synthesis, the cofactor pool that governs mitochondrial output and cellular repair capacity — tissue that depends on sustained energy production and the ability to rebuild after stress. Trials designed around body composition rather than scale weight represent a more informative read on what metabolic therapy is actually doing to the structures that carry a person through a long life.
Original published by LT Wire.